While EPO demonstrates clear metabolic benefits in preclinical models, its erythropoietic activity poses clinical limitations—particularly in individuals with obesity-related comorbidities—due to risks such as polycythemia and thrombosis. The gene discussed is EPO; the disease is obesity due to melanocortin 4 receptor deficiency.